{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109860","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.436425+00:00","generated_at":"2026-05-16T21:22:24.596975+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics Q3 net loss $3.0M; cash runway into Q4 2026; clinical updates on APR-1051 and ATRN-119","bullets":["Cash and cash equivalents $13.7M as of Sep 30, 2025; operating loss $3.1M vs $4.1M YoY.","Net loss $3.0M ($0.47 per basic share) on 6.4M weighted avg shares; R&D expenses $1.6M.","APR-1051 Phase 1: 3 of 4 patients at 100mg QD achieved stable disease; dose escalation advanced to 150mg.","ATRN-119: RP2D set at 1,100mg QD; enrollment paused to explore combination studies with radiation.","Cash sufficient into Q4 2026; anticipates value-creating catalysts in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109860","json":"https://secwatch.observer/filing/0001104659-25-109860.json","markdown":"https://secwatch.observer/filing/0001104659-25-109860.md","text":"https://secwatch.observer/filing/0001104659-25-109860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/0001104659-25-109860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/apre-20251112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:22:24.596975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}